Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation

Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation

Objectives: This study aimed to develop a piperacillin population PK model for critically ill Brazil-ian patients and describe interethnic variation using an external validation. Methods: Plasma samples were obtained from 24 ICU patients during the fifth day of piperacillin treatment and assayed by...

Full description

Bibliographic Details
Main Authors:	Cristina Sanches, Geisa C. S. Alves, Andras Farkas, Samuel Dutra da Silva, Whocely Victor de Castro, Farah Maria Drummond Chequer, Francisco Beraldi-Magalhães, Igor Rafael dos Santos Magalhães, André de Oliveira Baldoni, Mark D. Chatfield, Jeffrey Lipman, Jason A. Roberts, Suzanne L. Parker
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Antibiotics
Subjects:	piperacillin pharmacokinetics critically ill ethnic group antimicrobial
Online Access:	https://www.mdpi.com/2079-6382/11/4/434

Similar Items

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
by: Daniel J. Selig, et al.
Published: (2022-05-01)

Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae
by: Vicente Merino-Bohórquez, et al.
Published: (2021-03-01)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
by: Xueting Wang, et al.
Published: (2023-02-01)

Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
by: Kohama H, et al.
Published: (2017-02-01)

Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia
by: Noriyuki Ishihara, et al.
Published: (2020-03-01)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
by: Jihyun Yang, et al.
Published: (2023-06-01)

Modeling Pharmacokinetics in Individual Patients Using Therapeutic Drug Monitoring and Artificial Population Quasi-Models: A Study with Piperacillin
by: Gellért Balázs Karvaly, et al.
Published: (2024-03-01)

Intermittent Short-Term Infusion vs. Continuous Infusion of Piperacillin: Steady State Concentrations in Porcine Cervical Spine Tissue Evaluated by Microdialysis
by: Elisabeth Krogsgaard Petersen, et al.
Published: (2022-07-01)

Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
by: Sabine F. Maarbjerg, et al.
Published: (2022-10-01)

Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics
by: David Busse, et al.
Published: (2021-08-01)

Piperacillin/Tazobactam-Induced Neutropenia: A Case Report
by: Hayati DEMİRASLAN, et al.
Published: (2012-03-01)

A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept
by: Stan J. F. Hartman, et al.
Published: (2020-12-01)

Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools
by: Ferdinand Anton Weinelt, et al.
Published: (2022-06-01)

Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial
by: Stefan Hagel, et al.
Published: (2019-06-01)

Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam
by: Chi-Hao Shao, et al.
Published: (2022-01-01)

Is Piperacillin-Tazobactam an Appropriate Empirical Agent for Hospital-Acquired Sepsis and Community-Acquired Septic Shock of Unknown Origin in Australia?
by: Alice Gage-Brown, et al.
Published: (2022-05-01)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
by: Christina Scharf, et al.
Published: (2020-03-01)

Impact of extended-infusion piperacillin-tazobactam in a Canadian community hospital
by: April J. Chan, et al.
Published: (2023-03-01)

Simple HPLC-UV Method for Piperacillin/Tazobactam Assay in Human Plasma
by: Khaled Abdelkawy, et al.
Published: (2023-02-01)

Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market
by: Melissa Orzechowski Xavier, et al.

A Case of DRESS Syndrome Associated with Piperacillin-Tazobactam Treatment and Literature Review
by: Seven ULUDOKUMACI, et al.
Published: (2012-12-01)

Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients
by: Javier Martínez-Casanova, et al.
Published: (2023-03-01)

Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients
by: Jarne Verhaeghe, et al.
Published: (2022-08-01)

Piperacillin/tazobactam in modern clinical practice
by: Igor Bereznyakov
Published: (2022-05-01)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock
by: Yang Sun, et al.
Published: (2023-06-01)

Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study
by: Kazutaka Oda, et al.
Published: (2021-09-01)

Development and validation of a quantitative HPLC/MS/MS method for the determination of piperacillin in blood plasma
by: Vladimir I. Petrov, et al.
Published: (2023-06-01)

Piperacillin Steady State Concentrations in Target Tissues Relevant for PJI Treatment—A Randomized Porcine Microdialysis Study Comparing Continuous Infusion with Intermittent Short-Term Infusion
by: Hans Christian Rasmussen, et al.
Published: (2023-03-01)

Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature
by: Musa Alzahrani, et al.
Published: (2018-08-01)

Linguistic and cultural adaptation to the Portuguese language of antimicrobial dose adjustment software
by: Samuel Dutra da Silva, et al.
Published: (2020-01-01)

Steady-State Piperacillin Concentrations in the Proximity of an Orthopedic Implant: A Microdialysis Porcine Study
by: Johanne Gade Lilleøre, et al.
Published: (2023-03-01)

Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study
by: Heenam Seo, et al.
Published: (2022-08-01)

Susceptive piperacillin-tazobactam-induced Evans syndrome after radical resection of esophageal cancer: A rare case report
by: Yan Li, et al.
Published: (2023-12-01)

Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance
by: Thibaud Besnard, et al.
Published: (2019-01-01)

Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients
by: Tatchanapong Chongcharoenyanon, et al.
Published: (2021-07-01)

Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity
by: Milani Morteza, et al.
Published: (2019-01-01)

Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa
by: Đorđević Zorana, et al.
Published: (2013-01-01)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
by: Anthony Martin Mena, et al.
Published: (2023-08-01)

Piperacillin/Tazobactam Co-Delivery by Micellar Ionic Conjugate Systems Carrying Pharmaceutical Anions and Encapsulated Drug
by: Katarzyna Niesyto, et al.
Published: (2024-01-01)

Evaluation of Piperacillin/Tazobactam Use and Resistance Pattern in a Teaching Hospital, Northwest Iran
by: Afshin Shiva, et al.
Published: (2022-06-01)